Pharma Marketing 2010 - Invest up to 50% less and be among the experts from the industry

North West Business Group30 September 2010, Frankfurt, Germany.
Pharma Marketing 2010 in Frankfurt provides a key platform for Europe's pharmaceutical industry stakeholders, such as yourself, to discover how best to tackle the key challenges of a price-sensitive and increasingly competitive and rapidly changing market.

This event offers the perfect setting for industry peers to present their ideas and successes directly to key decision makers from leading pharmaceutical companies. At this meeting you will meet and interact with senior level marketing executives, through a number of one-on-one meetings and networking activities.

They will discuss the challenges and strategies used to enhance online communication, customer relationship, strengthen brand awareness and improve profitability in marketing. This is your one-stop-shop to the most up to date online marketing strategies, regulatory low down, measuring ROI, analytical tools and more such as:

  • 5 reasons why Pharma should not do E-marketing
  • The successful commercialisation of a pharma brand start with an effective launch
  • Forecasting is easy, communication is difficult
  • Achieving Launch Excellence in a Challenging Pharma Marketplace
  • The Doctor - Patient - Pharma: a triangle about a patient's health improvement.
  • Balancing "old" and "new" marketing strategies
  • Brand Management
  • Why Online Belongs to the Pharma Marketing Mix

Joins some of the experts like:

  • IMS heath, Director commercial effectiveness EMEA
  • UCB Pharma, Head of eStrategies
  • Novartis Oncology Region Europe, Regional Brand Leader
  • Eli Lilly, Director Human Resources
  • Astellas Pharma, Marketing Director
  • Genzyme, Associate Director Global Commercial Effectiveness and Development
  • AstraZneca, VP Global Marketing
  • Allergan, Director Consumer Marketing
  • Google, Industry Head
  • And many more ...

Who should attend?
This conference is designed to attract key decision makers from the Pharmaceutical industry: Presidents, Managing Directors, Country Managers, General Managers, Vice Presidents, Regional Directors/ Heads, Directors, Department Heads, Managers.

For further information and registration, please visit:
http://nwbg.eu/all-events/pharma-marketing-2010/

Most Popular Now

Cannabis extract helps reset brain function in psy…

Research from King's College London has found that a single dose of the cannabis extract cannabidiol can help reduce brain function abnormalities seen in people with psyc...

For first time in 40 years, cure for acute leukemi…

Acute myeloid leukemia is one of the most aggressive cancers. While other cancers have benefitted from new treatments, there has been no encouraging news for most leukemi...

New cancer treatment uses enzymes to boost immune …

Researchers at The University of Texas at Austin have developed a new approach to treating cancer using enzyme therapy. The enzyme, PEG-KYNase, does not directly kill can...

Bayer accelerates six new startups

Changing the experience of health: that's the focus of the six startups which the Bayer G4A team has included in the Accelerator program this year. The young companies fr...

Novartis receives European Commission approval of …

Novartis today announced that the European Commission (EC) has approved Kymriah® (tisagenlecleucel, formerly CTL019). The approved indications are for the treatment of pe...

Shire completes sale of oncology franchise

Shire plc (LSE: SHP, NASDAQ: SHPG) announces today that it has completed the sale of its Oncology franchise to Servier S.A.S. for $2.4 billion. The franchise includes the...

Antioxidant reduces risk for second heart attack, …

Doctors have long known that in the months after a heart attack or stroke, patients are more likely to have another attack or stroke. Now, a paper in the Journal of the A...

Novartis to divest the Sandoz US dermatology busin…

Novartis today announced it has agreed to sell selected portions of its Sandoz US portfolio, specifically the Sandoz US dermatology business and generic US oral solids po...

SOLAR-1 trial of Novartis investigational alpha-sp…

Novartis today announced the global Phase III SOLAR-1 trial evaluating the investigational alpha-specific PI3K inhibitor BYL719 (alpelisib) has met the primary endpoint s...

New tablet production facility in Ingelheim: Cente…

Boehringer Ingelheim held a groundbreaking ceremony for the construction of a new production facility for innovative drugs. This new Solids Launch facility will focus on ...

Tezepelumab granted Breakthrough Therapy Designati…

AstraZeneca and its partner Amgen Inc. (Amgen) today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for tezepelumab...

Pfizer terminates domagrozumab (PF-06252616) clini…

Pfizer Inc. (NYSE: PFE) announced that it is terminating two ongoing clinical studies evaluating domagrozumab (PF-06252616) for the treatment of Duchenne muscular dystrop...